Yuki Katsuya

Tokyo, 1040045, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access.

Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access.

Journal: ESMO real world data and digital oncology

Published: March 19, 2026

Impact of travel costs on disparities in precision oncology clinical trials.

Impact of travel costs on disparities in precision oncology clinical trials.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.

A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.

Journal: Investigational new drugs

Published: January 15, 2026

Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.

Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 23, 2025

Drug-drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors.

Drug-drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: September 22, 2025

Humoral and T-cell immune responses to coronavirus disease 2019 vaccines in patients with hematological malignancies.

Humoral and T-cell immune responses to coronavirus disease 2019 vaccines in patients with hematological malignancies.

Journal: Japanese journal of clinical oncology

Published: September 03, 2025

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study.

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study.

Journal: Investigational new drugs

Published: August 05, 2025

Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events.

Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events.

Journal: Cancer chemotherapy and pharmacology

Published: July 31, 2025

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

Journal: ESMO open

Published: July 09, 2025

Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends.

Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends.

Journal: Cancers

Published: May 07, 2025

Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study.

Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study.

Journal: BMC research notes

Published: December 18, 2024

An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.

An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.

Journal: Investigational new drugs

Published: December 11, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026